METHODS: Multicenter prospective observational study to investigate the clinical significance of serum SCCA2 in children as a biomarker for AD was performed. Patients with AD younger than 16 and age-matched healthy children without any allergic disease were enrolled in the study. Severity of AD was evaluated by using the objective SCORAD (O-SCORAD). Serum levels of SCCA2 and TARC were measured with ELISA.
RESULTS: Totals of 176 patients with AD and 159 non-allergic healthy children were tested. Serum levels of SCCA2 and TARC were significantly correlated with O-SCORAD with Spearman’s correlation coefficients of 0.622 and 0491, respectively. According to improvement of the symptoms by a standard treatment with topical steroids and emollients, serum levels of SCCA2 and TARC were significantly reduced. ROC analysis to diagnose AD yielded AUC at 0.929 and 0.871, respectively. Both the markers in normal children were higher in young infants.
CONCLUSIONS: SCCA2 is a reliable biomarker for AD in children and may be superior to TARC.